HTHarald Treuer

Harald Treuer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Harald Treuer has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • M Kocher

    Department of Stereotaxy and functional Neurosurgery, University Hospital of Cologne, Köln, Germany

    6 shared publications
  • Volker Sturm

    Department of Stereotactic and Functional Neurosurgery, University of Cologne Cologne, Germany

    6 shared publications
  • M Hoevels

    Department of Stereotaxy and functional Neurosurgery, University Hospital of Cologne, Köln, Germany

    4 shared publications
  • K Jablonska

    Department of Radiation Oncology, University Hospital of Cologne, Köln, Germany

    3 shared publications
  • M Ruge

    Department of Stereotaxy and Functional Neurosurgery, Centre of Neurosurgery, Köln, Germany

    3 shared publications
  • M. Kocher

    Klinik und Poliklinik für Strahlentherapie, Uniklinik Köln, Köln, Deutschland

    3 shared publications

Latest Publications

  • Open Access

    Use of dose-area product to assess plan quality in robotic radiosurgery

    by Markus Eichner, Alexandra Hellerbach, Mauritius Hoevels, Klaus Luyken, Michael Judge, Daniel Rueß, Maximilian Ruge, Martin Kocher, Stefan Hunsche, Harald Treuer

  • P05.38 Stereotactic radiosurgery of benign brain tumors in elderly patients: Evaluation of clinical outcome and toxicity

    by R Daniel, V Weyer, M Hoevels, S Grau, K Jablonska, J Tutunji, M Kocher, H Treuer, M Ruge

    Stereotactic radiosurgery (SRS) is widely accepted as a therapeutic option for benign brain tumors such as meningioma and neurinoma; however, detailed data on outcomes and toxicity especially in the elderly population have not yet been reported. In this single center retrospective analysis we consecutively included all patients aged ≥ 60 years with benign intracranial tumors (meningiomas, neurinomas) who underwent single fraction SRS by use of modified linear accelerator (LINAC) or Cyberknife® between 1991 and 2018. Patient data were analyzed in terms of tumor control (defined as no further intervention required), symptom control (stable clinical condition), co-morbidities and incidence of early and late treatment related complications (rated by using the Common Terminology Criteria for Adverse Events, CTCAE; v4.03). We identified 224 patients with either vestibular schwannoma (n=147) or meningioma (n=77). The median age was 68 yr (range, 60–84 yr), and the mean and median follow-up were 55 and 41 mo (range, 2–227 mo), respectively. Tumor margins were irradiated with a median dose of 12 Gy (range, 10–18.7 Gy), and the median tumor volume was 2.3 ml (range, 0.1–23.7 ml). Actuarial local tumor control rates at 2, 5, and 10 yr after SRS were 98%, 94%, and 90%, respectively. Mild or moderate adverse events were noted in 41 cases (18%). No severe adverse event was observed during early and late follow up. SRS provides favorable tumor control and a low risk of treatment related adverse early and/or late events. Thus, SRS should be taken into account as treatment option for benign intracranial tumors in elderly patients.


  • P05.40 Clinical and radiological outcome of vestibular schwannomas (Koos grade I - IV) after stereotactic radiosurgery

    by R Daniel, L Poehlmann, H Treuer, M Kocher, K Jablonska, S Grau, M Ruge

    In the management of vestibular schwannoma (VS) stereotactic radiosurgery (SRS) has evolved as widely accepted treatment option for small-sized tumors (Koos I and II). For larger VS (Koos III and IV) microsurgery is treatment of choice. However, for patients not suitable for microsurgery SRS might also be an alternative that balances tumor control, hearing preservation and adverse effects. The purpose of this analysis was to evaluate the efficacy and toxicity of SRS for different Koos grades including VS Koos III and IV. In this single center retrospective analysis (1991 - 2016) we included all patients with previously untreated VS who underwent single session LINAC or Cyberknife® based SRS. Patient data were analyzed and correlated using cox proportional hazard model in terms of the different Koos grades. Data analysis considered tumor control, preservation of serviceable hearing, course of median pure tone averages (PTA) at last follow up and procedure related early and late adverse events rated by Common Terminology Criteria for Adverse Events (CTCAE; v4.03). 265 patients (median age 59 years, range 17–84) were identified with a mean follow-up of 50.9 months (range 3–265 months). Mean tumor volume was 1.8 ml (range 0.1–23.7 ml). The mean marginal dose was 12.4 Gy ± 0.8 (range 11–20) and the mean isodose was 69.3 % ± 12.5 (range 32.9–86.2). 193 patients were considered as Koos grade I or II and 72 patients as grade III or IV. Actuarial tumor control was 98.5%, 88% and 88% after 2, 5 and 10 years respectively without significant difference between Koos grades I/II vs III/IV (hazard ratio (HR) 1.1, p=0.8, 95% CI, 0.4–3.6). Likewise, median PTA increase of Koos I/II tumors compared to Koos III/IV tumors revealed no significant difference (HR 0.5, p=0.07, 95% CI, 0.3–1.0). New permanent CN V and VII impairment could be objectified in 7.1% (n=19/265). The rate of permanent CN V and CN VII impairment showed no significant difference between Koos grades I/II vs III/IV (HR 0.5, p=0.07, 95% CI, 0.3–1.0). SRS for VS shows reliable long term tumor control and a high rate of hearing preservation and with low permanent side effects. Therefore, SRS can be proposed as safe and effective treatment option for VS, even with higher Koos grades.


  • P05.37 Hypofractionated radiosurgery for benign skull base tumors

    by R Daniel, C Hamisch, S Grau, K Jablonska, C Baues, M Kocher, H Treuer, M Ruge

    The use of single fraction stereotactic radiosurgery (SRS) is limited by tumour size (>3cm) and/or close proximity to critical structures (e.g. cranial nerves/optical pathway/pituitary gland). Here we present data using hypofractionated SRS (hSRS) for the treatment of benign skull base tumors either > 3 cm and/or neighboring critical structures. In this single center retrospective analysis we consecutively included all patients with benign skull base tumors (meningeomas, nonsecreting pituitary adenomas, schwannomas) who underwent Cyberknife® hSRS using a tumor surface dose of 25 Gy applied in five fractions (isodose level 70–80%) between 2012 and 2016 with a minimum follow-up of 6 months. Patient data were analyzed in terms of tumor control (defined as no further intervention required), symptom control (stable clinical condition) and incidence of early and late treatment related complications (rated by using the Common Terminology Criteria for Adverse Events, CTCAE; v4.03). 33 patients (f:m = 20:13, median age = 58 years) were treated with hSRS. Tumor entities were meningiomas (n=22), pituitary adenomas (n=8), vestibular- (n=1) and trigeminal nerve schwannomas (n=2). 42% underwent surgery prior hSRS. Mean tumor volume was 9.4 ml (0.6–35 ml). Median follow-up was 23 months (6–52 months). The actuarial 1-, 2-, and 4-year tumor control rate was 100%, 94.5% and 94.5%, respectively. Symptoms improved in 38% (n=8) of symptomatic cases (n=21). Transient adverse events (CTCAE grade I and II) were observed in 9% of the cases (headache n=1, arm paresis n=1, partial alopecia n=1). No permanent adverse events were observed. Our treatment results show low rates of mild adverse events and encouraging tumor control rates which are consistent with those reported in literature.

  • Computergesteuerte Hochpräzisionsbestrahlung

    by D. Rueß, M. Kocher, H. Treuer, M. I. Ruge

    Zusammenfassung Die Bestrahlung von Tumoren im Gehirn stellt grundsätzlich eine besondere Herausforderung dar, da sich strahlenempfindliche Risikostrukturen und die zu behandelnde pathologische Veränderung meist in sehr enger Lagebeziehung zueinander befinden und Schäden an Nervengewebe ab einem gewissen Maß irreversibel sind. Dies setzt daher besonders präzise Techniken voraus, um effektiv und zugleich schonend behandeln zu können. Die Stereotaxie, als Subspezialität der Neurochirurgie, hat über mehrere Jahrzehnte verschiedene hoch präzise lokale Bestrahlungsverfahren hierfür entwickelt. Hierzu gehören u. a. die intrazerebrale Anwendung der interstitiellen Brachytherapie (SBT; stereotaktische Brachytherapie) und die stereotaktische Radiochirurgie (SRS). Letztere hat insbesondere in den letzten 20 Jahren mit der Entwicklung computergesteuerter Bestrahlungsgeräte (z. B. Cyberknife) an Bedeutung gewonnen.

  • P36 Optimizing stimulation effects of DBS electrodes by a combined analysis of segmented MRI and VTA data

    by Judith Coenen, Julia Buhlmann, H. Treuer, M. Maarouf, V. Sturm, Peter A. Tass, Christian Hauptmann

  • Stereotactic LINAC Radiosurgery for Glomus Jugulare Tumors: Long-Term Follow-Up

    by M. Maarouf, J. Voges, F. El Majdoub, H. Treuer, M. Kocher, V. Sturm

    Background: The optimal treatment of glomus jugulare tumors (GJTs) of the skull base remains controversial. Surgical excision can be associated with a high incidence of cranial nerve injury and decreased quality of life. Fractionated radiotherapy can control the majority of these tumors, but disadvantages are a prolonged therapy interval and exposition of adjacent brain tissue to irradiation. We present long-term results of LINAC radiosurgery (LINAC-RS) in the management of GJTs. Methods: From May 1991 through August 2004, 21 GJTs patients (F:M = 17:4; age: 29–80 years; median: 60 years) were treated with stereotactic LINAC-RS for ongoing growth of either a primary tumor or of residual tumor following surgery. Thirteen of 21 patients with a median follow-up of 7.4 years (range: 5–12 years) were selected for retrospective analysis. A median single dose of 15 Gy (range: 11–20 Gy) was applied to the surface of the tumor. Results: Following LINAC-RS, 9 of the 13 patients (69%) had improved clinically and 4 (31%) were unchanged. Accessible neurological signs improved in 3 (23%) and remained stable in 9 (69%). MR examinations showed tumor shrinkage in 9 (69%) and no further progression in 4 patients (31%). Conclusions: This study shows that stereotactic LINAC-RS for GJTs management is highly effective providing long-term tumor control. Because of its low rate of side-effects, LINAC-RS may be an attractive alternative to surgery and/or fractionated radiotherapy for patients with GJTs.

  • Geometrical and dosimetrical characterization of the photon source using a micro-multileaf collimator for stereotactic radiosurgery

    by H Treuer, M Hoevels, K Luyken, S Hunsche, M Kocher, R-P M Ller, V Sturm

    A micro-multileaf collimator (microMLC) for stereotactic radiosurgery is used for determination of the spatial intensity distribution of the photon source of a linear accelerator. The method is based on grid field dose measurements using film dosimetry and is easy to perform. Since the microMLC does not allow 'direct' imaging of the photon source, special software has been developed to analyse grid field measurements. Besides the source-density function, grid field analysis yields the position of the focal spot in the room laser coordinate system of the linear accelerator and the position of the treatment head rotation axis and the inclination angle of the leaf bank. Thus the method can be used for base dosimetry and for quality assurance in radiosurgery using a microMLC.


  • On isocentre adjustment and quality control in linear accelerator based radiosurgery with circular collimators and room lasers

    by H Treuer, M Hoevels, K Luyken, A Gierich, M Kocher, R-P Müller, V Sturm

    We have developed a densitometric method for measuring the isocentric accuracy and the accuracy of marking the isocentre position for linear accelerator based radiosurgery with circular collimators and room lasers. Isocentric shots are used to determine the accuracy of marking the isocentre position with room lasers and star shots are used to determine the wobble of the gantry and table rotation movement, the effect of gantry sag, the stereotactic collimator alignment, and the minimal distance between gantry and table rotation axes. Since the method is based on densitometric measurements, beam spot stability is implicitly tested. The method developed is also suitable for quality assurance and has proved to be useful in optimizing isocentric accuracy. The method is simple to perform and only requires a film box and film scanner for instrumentation. Thus, the method has the potential to become widely available and may therefore be useful in standardizing the description of linear accelerator based radiosurgical systems.


    • 15 June 2000
      • Vol. 88  (12) , 2796-802

    Brachytherapy: Results of two different therapy strategies for patients with primary glioblastoma multiforme.

    by R W Koot, M Maarouf, M C Hulshof, J Voges, H Treuer, C Koedooder, V Sturm, D A Bosch

    In the current study, the authors describe and compare two different strategies of brachytherapy for the treatment of patients with primary glioblastoma multiforme (GBM). The study was comprised of 84 patients. Forty-five patients were implanted with permanent or temporary low activity iodine-125 ((125)I) seeds in Cologne and 21 patients were implanted with temporary iridium-192 ((192)Ir) wires in Amsterdam. Both groups received external beam radiation therapy (EBRT); the (125)I group received 10-30 grays (Gy) with the implant in situ and the (192)Ir group received 60 Gy before implantation. In Cologne, implantation was performed after a diagnostic stereotactic biopsy whereas in Amsterdam implantation took place after cytoreductive diagnostic surgery. In addition, 18 patients in Amsterdam served as a control group. This group received only EBRT after cytoreductive surgery. In both groups the mean age of the patients was between 50-55 years, with 80% of the patients age > 45 years. The mean implantation volume encompassed by the referenced isodose was 23 cm(3) for (125)I and 48 cm(3) for (192)Ir. Initial dose rates were 2. 5-2.9 centigrays (cGy)/hour for permanent (125)I, 4.6 cGy/hour for temporary (125)I, and 44-100 cGy/hour (mean, 61 cGy) for (192)Ir. A total dose of 50-60 Gy, 60-80 Gy, and 40 Gy, respectively, was administered at the outer margins of the tumor. The median survival was approximately 16 months for both the (125)I group and the (192)Ir group. This was 6 months longer than the median survival in the control group. Reoperations were performed in 4 patients in the (125)I group (9%) versus 7 patients in the (192)Ir group (33%). No complications or late reactions were reported in the (125)I group, whereas one case of hemorrhage and three cases of delayed stroke were observed in the (192)Ir group. The equal median survival times in these two brachytherapy groups with such different dose rate radiation schedules support the hypothesis that dose rate does not play a major role in the survival of patients with primary GBM.